The European Medicines Agency issued a negative "trend" vote for Biotech Inc.'s (Nasdaq: XBIT) marketing authorization application for its candidate antibody for the treatment of colorectal cancer. The stock price plunged $6.79 to close at $10.23.
Biotech receives negative trend vote
April 21, 2017 at 19:13 PM EDT
